{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:12:31Z","timestamp":1778724751951,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA072720"],"award-info":[{"award-number":["P30CA072720"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ucl.2026.02.001","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:54:30Z","timestamp":1773816870000},"page":"183-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["High Risk Prostate Cancer: What is it?"],"prefix":"10.1016","volume":"53","author":[{"given":"Melinda Z.","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Golombos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saum","family":"Ghodoussipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2026.02.001_bib1","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/pros.24041","article-title":"Prostate cancer-specific mortality burden by risk group among men with localized disease: implications for research and clinical trial priorities","volume":"80","author":"Dee","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.ucl.2026.02.001_bib2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer","volume":"18","author":"Devos","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","article-title":"High-risk prostate cancer-classification and therapy","volume":"11","author":"Chang","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ucl.2026.02.001_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11934-017-0703-x","article-title":"Radical prostatectomy for high-risk localized or node-positive prostate cancer: removing the primary","volume":"18","author":"Matulay","year":"2017","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.ucl.2026.02.001_bib5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/MOU.0b013e3283384101","article-title":"High-risk localized prostate cancer: role of radical prostatectomy","volume":"20","author":"Grubb","year":"2010","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib6","first-page":"33","article-title":"Surgical treatment of high-risk prostate cancer","volume":"67","author":"Soares","year":"2015","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.ucl.2026.02.001_bib7","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.euo.2024.05.016","article-title":"Effect of radical prostatectomy on survival for men with high-risk nonmetastatic prostate cancer features selected according to STAMPEDE criteria: an EMPaCT study","volume":"7","author":"Milonas","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ucl.2026.02.001_bib8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/MOU.0b013e3283620f60","article-title":"Results of surgery for high-risk prostate cancer","volume":"23","author":"Joniau","year":"2013","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib9","first-page":"58","article-title":"The evolving gleason grading system","volume":"28","author":"Chen","year":"2016","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.ucl.2026.02.001_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2559.2011.04003.x","article-title":"Gleason grading: past, present and future","volume":"60","author":"Delahunt","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.ucl.2026.02.001_bib11","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1200\/JCO.1993.11.11.2158","article-title":"Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer","volume":"11","author":"Pisansky","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2026.02.001_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0022-5347(01)65967-6","article-title":"Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy","volume":"156","author":"Lerner","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0090-4295(99)80091-0","article-title":"Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy","volume":"45","author":"Partin","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2026.02.001_bib14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/(SICI)1097-0142(19970115)79:2<337::AID-CNCR17>3.0.CO;2-1","article-title":"A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma","volume":"79","author":"Pisansky","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2026.02.001_bib15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ucl.2026.02.001_bib16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0090-4295(01)01441-8","article-title":"Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium","volume":"58","author":"Partin","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2026.02.001_bib17","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/S0022-5347(05)66349-5","article-title":"A catalog of prostate cancer nomograms","volume":"165","author":"Ross","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.juro.2008.10.033","article-title":"Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer","volume":"181","author":"Walz","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib19","article-title":"Development of ProCaRS clinical nomograms for biochemical failure-free survival following either low-dose rate brachytherapy or conventionally fractionated external beam radiation therapy for localized prostate cancer","volume":"7","author":"Warner","year":"2015","journal-title":"Cureus"},{"issue":"187\u20138","key":"10.1016\/j.ucl.2026.02.001_bib20","article-title":"Frontal lobe trauma in the elderly. Personality changes aren\u2019t always dementia","volume":"86","author":"Massey","year":"1989","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ucl.2026.02.001_bib21","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.urology.2007.08.055","article-title":"Contemporary evaluation of the D\u2019amico risk classification of prostate cancer","volume":"70","author":"Hernandez","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2026.02.001_bib22","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00345-022-04185-y","article-title":"External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort","volume":"41","author":"Hagens","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.juro.2007.03.105","article-title":"Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods","volume":"178","author":"Yossepowitch","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2014.01.020","article-title":"Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study","volume":"67","author":"Joniau","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12916-018-1019-5","article-title":"The Cambridge prognostic groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study","volume":"16","author":"Gnanapragasam","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.ucl.2026.02.001_bib27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41391-022-00621-7","article-title":"Revisiting current national Comprehensive Cancer Network (NCCN) high-risk prostate cancer stratification: a National Cancer Database analysis","volume":"27","author":"Garg","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ucl.2026.02.001_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2024.04.038","article-title":"Refining risk stratification of high-risk and locoregional prostate cancer: a pooled analysis of randomized trials","volume":"87","author":"Ravi","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/clinpract14020039","article-title":"Tissue-based genomic testing in prostate cancer: 10-year analysis of national trends on the use of prolaris, decipher, ProMark, and oncotype DX","volume":"14","author":"Bologna","year":"2024","journal-title":"Clin Pract"},{"key":"10.1016\/j.ucl.2026.02.001_bib30","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.19.02768","article-title":"Molecular biomarkers in localized prostate cancer: ASCO guideline","volume":"38","author":"Eggener","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2026.02.001_bib31","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","article-title":"A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling","volume":"66","author":"Klein","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib32","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/bjc.2012.39","article-title":"Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort","volume":"106","author":"Cuzick","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ucl.2026.02.001_bib33","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2012.46.4396","article-title":"Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort","volume":"31","author":"Cooperberg","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2026.02.001_bib34","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.juro.2013.06.017","article-title":"Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population","volume":"190","author":"Karnes","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib35","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the Decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib36","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1158\/1078-0432.CCR-14-2603","article-title":"Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer","volume":"21","author":"Blume-Jensen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2026.02.001_bib37","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","article-title":"Assessment of a polygenic risk Score in screening for prostate cancer","volume":"392","author":"McHugh","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2026.02.001_bib38","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1530\/ERC-18-0058","article-title":"Periprostatic fat tissue transcriptome reveals a signature diagnostic for high-risk prostate cancer","volume":"25","author":"Mangiola","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ucl.2026.02.001_bib39","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.eururo.2015.04.033","article-title":"Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes","volume":"68","author":"Tomlins","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib40","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ucl.2026.02.001_bib41","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1158\/0008-5472.CAN-16-0902","article-title":"Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome","volume":"76","author":"You","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2026.02.001_bib42","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2026.02.001_bib43","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","article-title":"Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy","volume":"3","author":"Zhao","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ucl.2026.02.001_bib44","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41391-021-00325-4","article-title":"A comparative study of PCS and PAM50 prostate cancer classification schemes","volume":"24","author":"Yoon","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ucl.2026.02.001_bib45","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.eururo.2016.04.023","article-title":"Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort","volume":"70","author":"Smith","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.001_bib46","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41391-021-00364-x","article-title":"Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype","volume":"24","author":"Han","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ucl.2026.02.001_bib47","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1093\/bioinformatics\/btaa1018","article-title":"MOVICS: an R package for multi-omics integration and visualization in cancer subtyping","volume":"36","author":"Lu","year":"2021","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ucl.2026.02.001_bib48","article-title":"Prostate cancer risk stratification in NRG oncology phase III randomized trials using multimodal deep learning with digital histopathology","volume":"8","author":"Tward","year":"2024","journal-title":"JCO Precis Oncol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:06:21Z","timestamp":1778724381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0094014326000017"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.001","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Risk Prostate Cancer: What is it?","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}